Lundbeck and to-BBB are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. Reportedly, the research could provide the backbone of new therapies for unserved brain diseases.
The collaboration with to-BBB is expected to provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.
to-BBB claims that its proprietary G-Technology is a safe technology for drug delivery to the brain and is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG), to safely enhance the delivery of free drug to the brain.
The company has shown proof of concept in several model systems, including brain microdialysis, pain inhibition, viral encephalitis and brain tumors, based on which Lundbeck will now evaluate the technology in their labs.
Pieter Gaillard, CSO of to-BBB, said: “We are very pleased to collaborate with Lundbeck. to-BBB’s brain delivery technology combined with Lundbeck’s knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”